FDA delays Karyopharm PDUFA to review extra information

The FDA has pushed back the PDUFA date for Karyopharm Therapeutics’ oncology drug selinexor by three months. Officials took the action after Karyopharm complied with the FDA’s request for more information.

READ  Septic Shock Drug Shows Promise for Personalized Medicine

Categories: Industry

Tagged as: ,

Leave a Reply